First principles pharmacokinetic modeling: A quantitative study on Cyclosporin

Computers and Chemical Engineering

Volumn 54, Issue , 2013, Pages 97-110

  Mošat', Andrej ^a   Lueshen, Eric ^a   Heitzig, Martina ^b   Hall, Cierra ^a   Linninger, Andreas A ^a   Sin, Gürkan ^b   Gani, Rafiqul ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Cyclosporin; Drug delivery; Immunosuppressant; Kinetic rate determination; Parameter estimation; Whole body physiologically based pharmacokinetics

Indexed keywords

BIOCHEMICAL REACTIONS; CYCLOSPORIN; IMMUNOSUPPRESSANT; KINETIC RATES; PHARMACOKINETIC MODELING; PHARMACOKINETIC PARAMETERS; TRANSPORT PARAMETERS; WHOLE BODY;

ANIMALS; BIOCHEMISTRY; CARDIOVASCULAR SYSTEM; CONSERVATION; DRUG DELIVERY; PARAMETER ESTIMATION; PHARMACOKINETICS; TISSUE;

PHYSIOLOGICAL MODELS;

EID: 84876882221     PISSN: 00981354     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compchemeng.2013.03.026     Document Type: Article

References (59)

1. Akhlaghi F., Ashley J., Keogh A., Brown K. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Therapeutic Drug Monitoring 1999, 21(1):8-16.
2. Bard Y. Nonlinear parameter estimation 1974, Academic Press, New York.
3. Bleck J.S., Schlitt H.J., Christians U., Thiesemann C., Strohmeyer S., Schottmann R., Kohlhaw K., Wonigeit K., Sewing K.F. Urinary excretion of cyclosporin and 17 of its metabolites in renal allograft recipients. Pharmacology 1989, 39(3):160-164.
4. Bonami P., Biegler L.T., Conn A.R., Cornuéjols G., Grossmann I.E., Laird C.D., Lee J., Lodi A., Margot F., Sawaya N., Wächter A. An algorithmic framework for convex mixed integer nonlinear programs. Discrete Optimization 2008, 5(2):186-204.
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and Industrial Health 1997, 13(4):407-484. PMID: 9249929.
6. Buss W.C., Stepanek J. Characterization of the inhibition of renal translation in the Sprague-Dawley rat following in vivo cyclosporin a. International Journal of Immunopharmacology 1993, 15(1):63-76.
7. Conn A.R., Gould N.I.M., Toint P.L. Global convergence of a class of trust region algorithms for optimization with simple bounds. SIAM Journal on Numerical Analysis 1988, 25(2):433-460.
8. De Buck S.S., Sinha V.K., Fenu L.A., Nijsen M.J., Mackie C.E., Gilissen R.A.H.J. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2007, 35(10):1766-1780. PMID: 17620347.
9. Delp M.D., Evans M.V., Duan C. Effects of aging on cardiac output, regional blood flow, and body composition in fischer-344 rats. Journal of Applied Physiology 1998, 85(5):1813-1822.
10. Donaldson J.R., Schnabel R.B. Computational experience with confidence regions and confidence intervals for nonlinear least squares. Technometrics 1987, 29(1):67-82.
11. Edginton A.N., Theil F., Schmitt W., Willmann S. Whole body physiologically-based pharmacokinetic models: Their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology 2008, 4(9):1143-1152.
12. El Tayar N., Mark A.E., Vallat P., Brunne R.M., Testa B., van Gunsteren W.F. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin a: Evidence from partition coefficients and molecular dynamics simulations. Journal of Medicinal Chemistry 1993, 36(24):3757-3764.
13. Espié P., Tytgat D., Sargentini-Maier M., Poggesi I., Watelet J. Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 2009, 41(3):391-407.
14. Fanghänel J., Fischer G. Thermodynamic characterization of the interaction of human cyclophilin 18 with cyclosporin a. Biophysical Chemistry 2003, 100(1-3):351-366.
15. Fuente R.L.d.l., Flores-Tlacuahuac A. Integrated design and control using a simultaneous mixed-integer dynamic optimization approach. Industrial & Engineering Chemistry Research 2009, 48(4):1933-1943.
16. Garg A., Balthasar J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34(5):687-709.
17. Gueorguieva I., Nestorov I.A., Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: Diazepam case study. Journal of Pharmacokinetics and Pharmacodynamics 2006, 33(1):1-27.
18. Hall C., Lueshen E., Mošat' A., Linninger A.A. Interspecies scaling in pharmacokinetics: A novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. Journal of Pharmaceutical Sciences 2012, 101(3):1221-1241.
19. Haritova A.M., Fink-Gremmels J. A simulation model for the prediction of tissue:plasma partition coefficients for drug residues in natural casings. Veterinary Journal (London, England: 1997) 2010, 185(3):278-284. PMID: 19709908.
20. Harjunkoski I., Jain V., Grossman I.E. Hybrid mixed-integer/constraint logic programming strategies for solving scheduling and combinatorial optimization problems. Computers & Chemical Engineering 2000, 24(2-7):337-343.
21. Heitzig M., Rong Y., Gregson C., Sin G., Gani R. Systematic multi-scale model development strategy for the fragrance spraying process and transport. Chemical Engineering & Technology 2012, 35(8):1381-1391.
22. Heitzig M., Sin G., Sales-Cruz M., Glarborg P., Gani R. Computer-aided modeling framework for efficient model development, analysis, and identification: Combustion and reactor modeling. Industrial & Engineering Chemistry Research 2010, 50(9):5253-5265.
23. Kawai R., Lemaire M., Steimer J.L., Bruelisauer A., Niederberger W., Rowland M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. Journal of Pharmacokinetics and Biopharmaceutics 1994, 22(5):327-365.
24. Kawai R., Mathew D., Tanaka C., Rowland M. Physiologically based pharmacokinetics of cyclosporine a: Extension to tissue distribution kinetics in rats and scale-up to human. The Journal of Pharmacology and Experimental Therapeutics 1998, 287(2):457-468. PMID: 9808668.
25. Kelly P.A., Wang H., Napoli K.L., Kahan B.D., Strobel H.W. Metabolism of cyclosporine by cytochromes p450 3A9 and 3A4. European Journal of Drug Metabolism and Pharmacokinetics 1999, 24(4):321-328.
26. Kieffer L.J., Thalhammer T., Handschumacher R.E. Isolation and characterization of a 40-kDa cyclophilin-related protein. The Journal of Biological Chemistry 1992, 267(8):5503-5507.
27. Kimura S., Oshima K., Okuda S., Sato K., Sato M., Terasako K., Nakasone H., Kako S., Yamazaki R., Tanaka Y., Tanihara A., Higuchi T., Nishida J., Kanda Y. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 2010, 45(6):1088-1094.
28. Kovarik J.M., Villamil F., Otero A., Levy G., Lynch S., Cillo U., Fischer L., Nashan B., Pollard S., De Carlis L. Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. Clinical Transplantation 2008, 22(1):68-75. PMID: 18217908.
29. Kulkarni, K. (2007). Mathematical modeling, problem inversion and design of distributed chemical and biological systems. Doctoral thesis, University of Illinois at Chicago, Chicago, IL, U.S.A.
30. Kulkarni K., Larsen P., Linninger A.A. Assessing chronic liver toxicity based on relative gene expression data. Journal of Theoretical Biology 2008, 254(2):308-318.
31. Kulkarni K., Zhang L., Linninger A.A. Model and parameter uncertainty in distributed systems. Industrial & Engineering Chemistry Research 2006, 45(23):7832-7840.
32. Laplanche R., Meno-Tetang G.M.L., Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34(3):373-400. PMID: 17431753.
33. Legg B., Rowland M. Cyclosporin: Measurement of fraction unbound in plasma. The Journal of Pharmacy and Pharmacology 1987, 39(8):599-603.
34. Linninger A.A., Xenos M., Sweetman B., Ponkshe S., Guo X., Penn R. A mathematical model of blood, cerebrospinal fluid and brain dynamics. Journal of Mathematical Biology 2009, 59(6):729-759.
35. Lucia A., Gattupalli R.R., Kulkarni K., Linninger A. A Barrier-Terrain methodology for global optimization. Industrial & Engineering Chemistry Research 2008, 47(8):2666-2680.
36. Lüpfert C., Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chemistry & Biodiversity 2005, 2(11):1462-1486.
37. Mendonza A.E., Gohh R.Y., Akhlaghi F. Blood and plasma pharmacokinetics of cyclosporin in diabetic kidney transplant recipients. Clinical Pharmacokinetics 2008, 47(11):733-742.
38. Nestorov I.S., Hadjitodorov S.T., Petrov I., Rowland M. Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates. AAPS pharmSci 1999, 1(4):E17.
39. Omar A.G., El-Mas M.M. Time-domain evaluation of cyclosporine interaction with hemodynamic variability in rats. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 2004, 18(6):461-468. PMID: 15770433.
40. Peters S.A., Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. Journal of Pharmacokinetics and Pharmacodynamics 2008, 35(1):1-30.
41. Petzold L.R. Recent developments in the numerical solution of differential/algebraic systems. Computer Methods in Applied Mechanics and Engineering 1989, 75(1- 3):77-89.
42. Ring B.J., Chien J.Y., Adkison K.K., Jones H.M., Rowland M., Jones R.D., et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessment of prediction methods of human clearance. Journal of Pharmaceutical Sciences 2011, PMID: 21541938.
43. Rooney W.C., Biegler L.T. Incorporating joint confidence regions into design under uncertainty. Computers & Chemical Engineering 1999, 23(10):1563-1575.
44. Rooney W.C., Biegler L.T. Design for model parameter uncertainty using nonlinear confidence regions. AIChE Journal 2001, 47(8):1794-1804.
45. Sadrieh N., Thomas P.E. Characterization of rat cytochrome p450 isozymes involved in the covalent binding of cyclosporin a to microsomal proteins. Toxicology and Applied Pharmacology 1994, 127(2):222-232. PMID: 8048065.
46. Sangalli L., Bortolotti A., Jiritano L., Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metabolism and Disposition 1988, 16(5):749-753.
47. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicology in Vitro: An International Journal Published in Association with BIBRA 2008, 22(2):457-467.
48. Tanaka C., Kawai R., Rowland M. Dose-dependent pharmacokinetics of cyclosporin a in rats: Events in tissues. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2000, 28(5):582-589.
49. Tang W., Zhang L., Linninger A.A., Tranter R.S., Brezinsky K. Solving kinetic inversion problems via a physically bounded gauss-newton (PGN) method. Industrial & Engineering Chemistry Research 2005, 44(10):3626-3637.
50. Thalhammer T., Kieffer L.J., Jiang T., Handschumacher R.E. Isolation and partial characterization of membrane-associated cyclophilin and a related 22-kDa glycoprotein. European Journal of Biochemistry/FEBS 1992, 206(1):31-37.
51. Toint P.L., Tomanos D., Weber-Mendonca M. A multilevel algorithm for solving the trust-region subproblem. Optimization Methods & Software 2009, 24:299-311.
52. Ursino M., Avanzolini G., Barbini P. Qualitative simulation of dynamic physiological models using the KEE environment. Artificial Intelligence in Medicine 1992, 4(1):53-73.
53. von Kleist M., Huisinga W. Physiologically based pharmacokinetic modelling: A sub-compartmentalized model of tissue distribution. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34(6):789-806.
54. von Kleist M., Huisinga W. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2009, 36(4-5):532-543.
55. Yang H., Elmquist W.F. The binding of cyclosporin a to human plasma: An in vitro microdialysis study. Pharmaceutical Research 1996, 13(4):622-627.
56. Yates J.W.T. Structural identifiability of physiologically based pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 2006, 33(4):421-439.
57. Zavala V.M., Biegler L.T. Large-scale parameter estimation in low-density polyethylene tubular reactors. Industrial & Engineering Chemistry Research 2006, 45(23):7867-7881.
58. Zavala V.M., Laird C.D., Biegler L.T. Interior-point decomposition approaches for parallel solution of large-scale nonlinear parameter estimation problems. Chemical Engineering Science 2008, 63(19):4834-4845.
59. Zhang L., Xue C., Malcolm A., Kulkarni K., Linninger A.A. Distributed system design under uncertainty. Industrial & Engineering Chemistry Research 2006, 45(25):8352-8360.